SCHEMBL9588276

SCHEMBL9588276

CCC(C([O])=O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FFAR2 O15552 1/20 0.49
▸ CYP2C9 P11712 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ POLB P06746 2/20 0.46
▸ BRD4 O60885 1/20 0.46
▸ KMT2A Q03164 2/20 0.45
▸ KCNQ2 O43526 2/20 0.45
▸ HTT P42858 1/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CRHBP P24387 1/20 0.41
▸ CRHR2 Q13324 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC7 Q8WUI4 1/20 0.41
▸ HDAC5 Q9UQL6 1/20 0.41
▸ SLC6A4 P31645 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711076 0.84 POLB (0.58) FFAR2CYP2C9CYP2C19POLBBRD4
SCHEMBL1742115 0.84 POLB (0.58) FFAR2CYP2C9CYP2C19POLBBRD4
SCHEMBL16075922 0.84 POLB (0.58) FFAR2CYP2C9CYP2C19POLBBRD4
SCHEMBL27515059 0.82 FFAR2 (0.48) FFAR2CYP2C9CYP2C19POLBBRD4
SCHEMBL23564521 0.82 FFAR2 (0.48) FFAR2CYP2C9CYP2C19POLBBRD4
SCHEMBL1289928 0.81 CYP2C9 (0.48) FFAR2CYP2C9CYP2C19POLBBRD4
SCHEMBL9587806 0.80 KCNQ2 (0.45) KCNQ2HTTHDAC4HDAC7HDAC5
SCHEMBL4517176 0.79 L3MBTL1 (0.49) FFAR2CYP2C9CYP2C19POLBKMT2A
SCHEMBL7629387 0.79 L3MBTL1 (0.61) FFAR2CYP2C9CYP2C19POLBKMT2A
SCHEMBL27676916 0.79 L3MBTL1 (0.61) FFAR2CYP2C9CYP2C19POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5190946-A Piperazine compounds restore sensitivity to drug resistant cancer cells HOFFMANN-LA ROCHE INC. (US) 1993-03-02 — — US claimed
EP-0443569-A2 Diamine derivatives and their use in oncology F. HOFFMANN-LA ROCHE AG (CH) 1991-08-28 — — EP claimed
US-5190946-A Piperazine compounds restore sensitivity to drug resistant cancer cells HOFFMANN-LA ROCHE INC. (US) 1993-03-02 — — US disclosed
EP-0443569-A2 Diamine derivatives and their use in oncology F. HOFFMANN-LA ROCHE AG (CH) 1991-08-28 — — EP disclosed
Send feedback